Medical Condition News

RSS

Statins may help protect stem cell transplant patients from GVHD

Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins may protect stem cell transplant patients from one of the most serious complications of the life-saving cancer therapy: graft-versus-host disease, or GVHD. The findings are reported in the Nov. 4 first edition of the journal Blood.

5 Dec 2009

NCI awards $55.4 million, multiple-year contract to Fred Hutchinson Cancer Research Center

The National Cancer Institute has awarded a $55.4 million, multiple-year contract to Fred Hutchinson Cancer Research Center to become the nation's sole operator of its Cancer Information Service Contact Center.

5 Dec 2009

Health experts address treatment gap in epilepsy management at AES Annual Meeting

Substantial progress has been made over the last 15 years in the healthcare community's ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy management has not reached most of the 50 million people around the world, including many of the nearly three million people in the United States who have the disorder.

5 Dec 2009

New findings shed light on heart attack symptoms

Researchers at Texas Health Presbyterian Hospital Dallas are investigating what symptoms could help doctors better spot heart attacks and if certain symptoms might indicate different types of heart attacks.

5 Dec 2009

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

Rituximab drug may reduce long-term complications of type 1 diabetes

New findings by UT Southwestern researchers suggest that a drug already used to treat autoimmune disorders might also help slow the destruction of insulin-producing cells in patients recently diagnosed with insulin-dependent (type 1) diabetes.

4 Dec 2009

First patient treated in Carticept Medical's Cartiva SCI study

Carticept Medical, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, today announced that the first patient has been treated in an international, multi-center study of the Company's Cartiva Synthetic Cartilage Implant (SCI). The study aims to determine the effectiveness of Cartiva SCI in comparison to arthrodesis (joint fusion), the current standard of care, for reducing the debilitating pain associated with osteoarthritis of the first metatarsophalangeal (MTP) joint.

4 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

Geisinger Health System's diabetic bundling program pays dividends

Diabetes is one of the nation's most prevalent chronic diseases, and Geisinger has created a "bundle" of best practice measures to improve the quality of diabetes care and outcomes.

4 Dec 2009

Overview of the important research and treatments in ADHD

Worldwide longitudinal studies performed since the 1970s have clearly shown that ADHD persists into adulthood. These findings have stimulated researchers to develop the therapeutic approaches for adult patients, especially in European countries where scientific and clinical interest in ADHD has increased.

4 Dec 2009

FNAC plays an increased role in the diagnosis of bone lesions

In recent years, fine-needle aspiration cytology (FNAC) has become a widely accepted procedure in the diagnosis of bone lesions. Rapid progress in immunocytochemistry and molecular genetics has increased the role of FNAC in the investigation of primary bone lesions.

4 Dec 2009

Watson Laboratories files an ANDA for generic version of Rozerem

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 8mg ramelteon tablets prior to the expiration of a patent owned by Takeda Pharmaceutical Company Limited.

4 Dec 2009

Cyberonics' FDA-approved VNS Therapy to be featured at the AES meeting

Cyberonics, Inc. announced today that Vagus Nerve Stimulation (VNS) Therapy, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, will be featured in 14 presentations at the American Epilepsy Society's (AES) Annual Meeting, taking place December 4-8 at the Hynes Convention Center in Boston, Massachusetts.

4 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

4 Dec 2009

Orthofix International announces the launch of its FUSION Lateral OA Brace

Orthofix International announced today that its sports medicine division, BREG, has expanded its successful line of FUSION® functional knee braces by introducing the FUSION® Lateral OA Brace, which features an ultra-thin low-profile hinge designed for individuals suffering from lateral compartment osteoarthritis (OA).

4 Dec 2009

IMF to stage presentation on multiple myeloma at ASH annual meeting

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.

4 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

Effective prevention of smoking among teenagers, particularly black teenagers, is narrowing the disparity in lung cancer rates between blacks and whites, according to a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The December issue has a special focus on tobacco.

4 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

Medical Condition News

Statins may help protect stem cell transplant patients from GVHD

NCI awards $55.4 million, multiple-year contract to Fred Hutchinson Cancer Research Center

Health experts address treatment gap in epilepsy management at AES Annual Meeting

New findings shed light on heart attack symptoms

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Rituximab drug may reduce long-term complications of type 1 diabetes

First patient treated in Carticept Medical's Cartiva SCI study

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Geisinger Health System's diabetic bundling program pays dividends

Overview of the important research and treatments in ADHD

FNAC plays an increased role in the diagnosis of bone lesions

Watson Laboratories files an ANDA for generic version of Rozerem

Cyberonics' FDA-approved VNS Therapy to be featured at the AES meeting

Preclinical data of Curis' HSP 90 inhibitor published

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Orthofix International announces the launch of its FUSION Lateral OA Brace

IMF to stage presentation on multiple myeloma at ASH annual meeting

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Effective prevention of smoking among teenagers narrows racial disparity in lung cancer rates

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News